Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.

Autor:	Solforosi L; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Kuipers H; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Jongeneelen M; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Rosendahl Huber SK; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., van der Lubbe JEM; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Dekking L; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Czapska-Casey DN; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Izquierdo Gil A; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Baert MRM; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Drijver J; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Vaneman J; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., van Huizen E; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Choi Y; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Vreugdenhil J; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Kroos S; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., de Wilde AH; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Kourkouta E; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Custers J; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., van der Vlugt R; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Veldman D; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Huizingh J; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Kaszas K; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Dalebout TJ; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands., Myeni SK; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands., Kikkert M; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands., Snijder EJ; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands., Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA., Böszörményi KP; Biomedical Primate Research Centre, Rijswijk, Netherlands., Stammes MA; Biomedical Primate Research Centre, Rijswijk, Netherlands., Kondova I; Biomedical Primate Research Centre, Rijswijk, Netherlands., Verschoor EJ; Biomedical Primate Research Centre, Rijswijk, Netherlands., Verstrepen BE; Biomedical Primate Research Centre, Rijswijk, Netherlands., Koopman G; Biomedical Primate Research Centre, Rijswijk, Netherlands., Mooij P; Biomedical Primate Research Centre, Rijswijk, Netherlands., Bogers WMJM; Biomedical Primate Research Centre, Rijswijk, Netherlands., van Heerden M; Non-Clinical Safety Toxicology/Pathology, Janssen Research and Development, Beerse, Belgium., Muchene L; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Tolboom JTBM; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Roozendaal R; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Brandenburg B; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Schuitemaker H; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Wegmann F; Janssen Vaccines and Prevention B.V., Leiden, Netherlands., Zahn RC; Janssen Vaccines and Prevention B.V., Leiden, Netherlands.
Jazyk:	angličtina
Zdroj:	The Journal of experimental medicine [J Exp Med] 2021 Jul 05; Vol. 218 (7).
DOI:	10.1084/jem.20202756
Abstrakt:	Safe and effective coronavirus disease-19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and durability of immunity and protective efficacy. We assessed one- and two-dose regimens of the Ad26.COV2.S vaccine candidate in adult and aged nonhuman primates (NHPs). A two-dose Ad26.COV2.S regimen induced higher peak binding and neutralizing antibody responses compared with a single dose. In one-dose regimens, neutralizing antibody responses were stable for at least 14 wk, providing an early indication of durability. Ad26.COV2.S induced humoral immunity and T helper cell (Th cell) 1-skewed cellular responses in aged NHPs that were comparable to those in adult animals. Aged Ad26.COV2.S-vaccinated animals challenged 3 mo after dose 1 with a SARS-CoV-2 spike G614 variant showed near complete lower and substantial upper respiratory tract protection for both regimens. Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen. Competing Interests: Disclosures: M.R.M. Baert, Y. Choi, J. Custers, D.N. Czapska-Casey, A.H. de Wilde, J. Drijver, J. Huizingh, M. Jongeneelen, K. Kaszas, E. Kourkouta, H. Kuipers, L. Muchene, R. Roozendaal, S.K. Rosendahl Huber, L. Solforosi, J.T.B.M. Tolboom, J.E.M. van der Lubbe, R. van der Vlugt, M. van Heerden, E. van Huizen, J. Vaneman, D. Veldman, J. Vreugdenhil, and R. Zahn are employees of Janssen Pharmaceutical Companies of Johnson & Johnson. D.H. Barouch reports grants from Janssen during the conduct of the study; grants from NIH, HJF/WRAIR, BMGF, DARPA, Gilead, Intima, Alkermes, CureVac, South Africa MRC, amfAR, Ragon Institute, MassCPR, Sanofi, Legend, and Zentalis; and personal fees from SQZ Biotech outside the submitted work. In addition, D.H. Barouch has a patent to COVID-19 vaccines licensed (Janssen). H. Schuitemaker reports "other" from Department of Health and Human Services BARDA (HHS0100201700018C) during the conduct of the study; and personal fees from Johnson & Johnson and Janssen Vaccines & Prevention B.V. outside the submitted work. F. Wegmann reports a patent to company pending and is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson. No other disclosures were reported. (© 2021 Solforosi et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu